Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 3, 2010

Kyowa Hakko Kirin to Sell Solasia’s Antiemetic Patch in Certain Asian Countries

  • Kyowa Hakko Kirin has obtained an exclusive right to market and sell Solasia Pharma’s antiemetic in Taiwan, Hong Kong, Singapore, and Malaysia. Sancuso is an extended-release transdermal system delivering the antiemetic granisetron, a 5-HT3 receptor antagonist.

    The therapy was approved by the FDA in September 2008 for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately and/or highly emetogenic chemotherapy for up to five consecutive days. ProStrakan launched Sancuso in the U.S. in the fourth quarter of 2008. In May 2008, Solasia acquired the exclusive right to Sancuso from ProStrakan for Japan, China, and other territories in Asia. Solasia retains full rights in Japan and China where it is currently conducting Sancuso clinical trials.

    According to the terms of the arrangement between Solasia and Kyowa Hakko Kirin, Solasia will receive an up-front fee as well as regulatory- and sales-related milestones. Kyowa Hakko Kirin will be responsible for all commercialization activities in Taiwan, Hong Kong, Singapore, and Malaysia. Solasia will supply the product to Kyowa Hakko Kirin in these territories. 

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »